Skip to main content
Signal8

ProPhase Labs, Inc. (PRPH)

ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

OTC:PRPHOTC (suspended from Nasdaq on Jan 5, 2026)Healthcare
+20.00%$0.0060
Mkt Cap$94K
EV-
Float13.9M
O/S15.59M
VOL3K sh
$ Vol$16
RVOL0.01×
Inst Own0.0%
SI0.4%
Net Cash/Sh-
Dilution
ProPhase Labs, Inc. logoOTC:PRPH$0.0060+20.00%

ProPhase Labs, Inc. (PRPH) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 24 SEC filings.

Shelf registration
S-3 filed Nov 12, 2024, effective Nov 20, 2024
Source: 10-Q filed Aug 19, 2026
At-the-market (ATM) program
Yes, sales agreement dated Oct 9, 2025
Source: 10-Q filed Aug 19, 2026
Warrants outstanding
8 warrant series recorded as outstanding
Most recent offering
PIPE, closed Jul 31, 2026
Source: 8-K filed Aug 6, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro